Wyeth' Unit Launches Gender-Age-Specific Adult Multivitamin Line
Developed to help meet the nutritional needs of women and men
Wyeth Consumer Healthcare, a division of Wyeth, has reported the availability of a new, gender and age-specific adult multivitamin line. It is developed to help meet the nutritional needs of women and men.
The Centrum Ultra line of multivitamins is specially formulated for women and men to help ensure that they are getting recommended amounts of key vitamins and minerals each day, based on one’ gender and age.
Paul Sturman, president of Wyeth Consumer Healthcare, said: “We listen closely to the needs of our consumers and combine these insights with the latest nutritional advances. Centrum Ultra provides a new, scientifically advanced option to meet consumers growing demand for gender-and age-based multivitamins.
Related Insight
Suppliers Directory
Aris Global - Integrated Software Solutions and Services for Life Sciences
Aris Global is a leading developer of integrated software solutions and services for pharmacovigilance and safety, regulatory affairs, clinical research and medical information.
Suppliers
Rovi CM / Rovi Alcala - Research, Development, Manufacturing and Marketing Services
The larger branch of Rovi Group is a fully-integrated Spanish specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of small molecules and speciality biologic drugs. The company was founded in 1946 and the group is quoted on the Madrid Stock Market since 2007. Revenues from 2010 were €158,6 M and takes count with over 800 employees. Due to our flexibility, transparency, expertise and constant dedication, we work hard to make every client feel like our most important one.
Suppliers
Chemonaut - The World of Chemistry at Your Fingertips
Chemonaut provides online compound sourcing and procurement services to life science companies.
Suppliers
NEUROFIT - Preclinical Research
NEUROFIT is a CRO (Contract Research Organisation) specialised in the evaluation of treatments for central (CNS) and peripheral nervous system (PNS) disorders, autoimmune diseases and for Oncology.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Advances in Sample Preparation for Metabolite Profiling
Published by Genevac
White Papers
Tips & Tricks - GPC/SEC: Copolymer Analysis in GPC/SEC 3 - Two-Dimensional Chromatography
Published by Polymer Standards Service
White Papers
Reduced Solvent Consumption and Operational Costs with Existing LC Systems
Published by Shimadzu PBR
White Papers
Earned Value Management, an approach for effectively managing pipeline value
Published by Kinapse
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.